Articles

Sort by
Previous Page Page 1 of 8 Next Page
  1. Research

    Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)

    Pegylated interferon alfa-2a (PEG-IFN-α-2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia (ET)...

    Lucia Masarova, C. Cameron Yin, Jorge E. Cortes, Marina Konopleva, Gautam Borthakur, Kate J. Newberry, Hagop M. Kantarjian, Carlos E. Bueso-Ramos and Srdan Verstovsek

    Experimental Hematology & Oncology 2017 6:30

    Published on: 9 November 2017

  2. Case report

    Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma

    The treatment algorithm for metastatic non-small cell lung cancers (NSCLCs) has been evolving rapidly due to the development of new therapeutic agents. Although guidelines are provided by National Comprehensiv...

    Shuyu D. Li, Annia Martial, Alexa B. Schrock and Jane J. Liu

    Experimental Hematology & Oncology 2017 6:29

    Published on: 6 November 2017

  3. Research

    Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

    Carfilzomib is approved in the United States and Europe for treatment of relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) and safety of carfilzomib in patients with rela...

    Jennifer Brown, Ruth Plummer, Todd M. Bauer, Stephen Anthony, John Sarantopoulos, Filip De Vos, Mike White, Marco Schupp, Ying Ou and Ulka Vaishampayan

    Experimental Hematology & Oncology 2017 6:27

    Published on: 3 October 2017

  4. Research

    Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients

    Post-transplant lymphoproliferative disorder is a well-recognized but rare complication of hematopoietic stem cell and solid organ transplant. Due to rarity of this disease, retrospective studies from major tr...

    Rohit Bishnoi, Ravneet Bajwa, Aaron J. Franke, William Paul Skelton IV, Yu Wang, Niraj M. Patel, William Birdsall Slayton, Fei Zou and Nam H. Dang

    Experimental Hematology & Oncology 2017 6:26

    Published on: 29 September 2017

  5. Review

    Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as a valuable approach in treatment of numerous malignant and none malignant hematologic disorders. However, relapse and poor ...

    Saeed Mohammadi, Amir Hossein Norooznezhad, Ashraf Malek Mohammadi, Hajar Nasiri, Mohsen Nikbakht, Najmaldin Saki, Mohammad Vaezi, Kamran Alimoghaddam and Ardeshir Ghavamzadeh

    Experimental Hematology & Oncology 2017 6:24

    Published on: 9 August 2017

  6. Review

    Pivotal regulators of tissue homeostasis and cancer: macrophages

    Macrophages are an essential component of innate immunity and play a vital role in inflammation and host defense. Based on immunological responses, the macrophages are classified into “activated” macrophage (M...

    Yulei Chen and Xiaobo Zhang

    Experimental Hematology & Oncology 2017 6:23

    Published on: 8 August 2017

  7. Short report

    Microfluidic device for primary tumor spheroid isolation

    Traditional two-dimensional (2-D) monolayer cell culture is vastly different from in vivo physiological conditions, which can lead to inaccurate or insufficient data in areas where response and efficacy within...

    Jiaojiao Zhou, Jimmy Su, Xiaotong Fu, Lei Zheng and Zhizhong Yin

    Experimental Hematology & Oncology 2017 6:22

    Published on: 7 August 2017

  8. Review

    Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

    B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies. Despite significant improvement on pa...

    Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu and Kenneth C. Anderson

    Experimental Hematology & Oncology 2017 6:20

    Published on: 14 July 2017

  9. Case report

    Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature

    Heparin-induced thrombocytopenia (HIT) is a life and limb-threatening condition caused by the binding of platelet-activating antibodies (IgG) to multimolecular platelet factor 4 (PF4)/heparin complexes because...

    Daniel E. Ezekwudo, Rebecca Chacko, Bolanle Gbadamosi, Syeda Batool, Sussana Gaikazian, Theodore E. Warkentin, Jo-Ann I. Sheppard and Ishmael Jaiyesimi

    Experimental Hematology & Oncology 2017 6:21

    Published on: 14 July 2017

  10. Research

    Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis

    Inflammation is a major feature of sickle cell disease (SCD). Low-dose methotrexate (MTX) has long been used in chronic inflammatory diseases. This pilot study examined the MTX effect on acute vaso-occlusive p...

    Silvia R. Brandalise, Rosemary Assis, Angelo B. A. Laranjeira, José Andrés Yunes and Pedro O. de Campos-Lima

    Experimental Hematology & Oncology 2017 6:18

    Published on: 19 June 2017

  11. Review

    The role of cullin4B in human cancers

    Cullin 4B (CUL4B) is a scaffold of the Cullin4B-Ring E3 ligase complex (CRL4B) that plays an important role in proteolysis and is implicated in tumorigenesis. Aberrant expression of CUL4B has been reported in ...

    Ying Li and Xin Wang

    Experimental Hematology & Oncology 2017 6:17

    Published on: 15 June 2017

  12. Research

    Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma

    Multiple myeloma (MM) is a type of hematological malignancy with significant heterogeneity in clinical features and prognosis. Cytogenetic abnormalities are the major factors affecting patient outcomes. Studie...

    GuoQing Wei, LiJun Wang, HanJin Yang, XiaoYan Han, GaoFeng Zheng, WeiYan Zheng, Jie Sun, JiMin Shi, WenJun Wu, Yi Zhao, DongHua He, Bo Wang, Zhen Cai and JingSong He

    Experimental Hematology & Oncology 2017 6:16

    Published on: 26 May 2017

  13. Research

    Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

    Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluat...

    Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, Chris Holland, Youssef Hijazi, Max S. Topp, Nicola Gökbuget, Patrick A. Baeuerle, Peter Kufer, Andreas Wolf and Matthias Klinger

    Experimental Hematology & Oncology 2017 6:14

    Published on: 18 May 2017

  14. Case report

    Cyclosporine is a potential curative treatment option for advanced thymoma

    Thymectomy can effectively cure most thymoma patients; however, patients with advanced thymoma typically require chemotherapy, which is associated with limited efficacy in this context. Here we provide the fir...

    Yusuke Isshiki, Hiroaki Tanaka, Yoshio Suzuki and Yukihiro Yoshida

    Experimental Hematology & Oncology 2017 6:13

    Published on: 3 May 2017

  15. Case report

    Metastatic squamous cell carcinoma of colon from esophageal cancer

    Esophageal cancer including squamous cell carcinoma (SCC) and adenocarcinoma represents 4% of all cancers in the United States. Patients with esophageal cancer frequently present with locally advanced disease,...

    Natasha Garg, Constance Stoehr, Yan Shi Zhao, Heather Rojas and Chung-Tsen Hsueh

    Experimental Hematology & Oncology 2017 6:11

    Published on: 18 April 2017

  16. Case report

    Adult acute precursor B-cell lymphoblastic leukemia presenting as hypercalcemia and osteolytic bone lesions

    Osteolytic bone lesions and hypercalcemia without peripheral blasts B-cell acute lymphoblastic leukemia (B-ALL) is reported in children but rarely seen in adults.

    Nikki Charlotta Paul Granacher, Zwi N. Berneman, Wilfried Schroyens, Ann L. R. Van de Velde, Anke Verlinden and Alain P. A. Gadisseur

    Experimental Hematology & Oncology 2017 6:9

    Published on: 11 April 2017

  17. Case report

    Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months

    The BRAF K601E mutation occurs in 5% of patients with melanoma, and is the third most common type of BRAF mutation. However, treatment with BRAF and mitogen-activated extracellular signal-regulated kinase (MEK...

    Riccardo Marconcini, Luca Galli, Andrea Antonuzzo, Simona Bursi, Claudia Roncella, Gabriella Fontanini, Elisa Sensi and Alfredo Falcone

    Experimental Hematology & Oncology 2017 6:6

    Published on: 21 March 2017

Previous Page Page 1 of 8 Next Page